Phoenix Wealth Advisors Buys 15,845 Shares of ARK Genomic Revolution ETF $ARKG

Phoenix Wealth Advisors bought a new stake in ARK Genomic Revolution ETF (BATS:ARKG) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,845 shares of the company’s stock, valued at approximately $859,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ARKG. Canal Insurance CO acquired a new position in ARK Genomic Revolution ETF during the 3rd quarter worth about $6,517,000. Gimbal Financial acquired a new stake in ARK Genomic Revolution ETF in the 3rd quarter valued at about $6,478,000. Commonwealth Equity Services LLC acquired a new stake in ARK Genomic Revolution ETF in the 3rd quarter valued at about $3,306,000. Baird Financial Group Inc. increased its position in ARK Genomic Revolution ETF by 0.3% in the 2nd quarter. Baird Financial Group Inc. now owns 73,722 shares of the company’s stock valued at $3,101,000 after acquiring an additional 255 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in shares of ARK Genomic Revolution ETF in the third quarter worth about $3,000,000.

ARK Genomic Revolution ETF Trading Up 1.9%

Shares of BATS ARKG traded up $0.83 during trading on Friday, reaching $45.45. The company had a trading volume of 4,007,262 shares, compared to its average volume of 3,542,198. ARK Genomic Revolution ETF has a 52 week low of $24.60 and a 52 week high of $58.83. The business’s 50 day moving average price is $49.73 and its 200-day moving average price is $37.76.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.